As of 2026-01-08, the EV/EBITDA ratio of Nurix Therapeutics Inc (NRIX) is -6.41. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NRIX's latest enterprise value is 1,688.27 mil USD. NRIX's TTM EBITDA according to its financial statements is -263.42 mil USD. Dividing these 2 quantities gives us the above NRIX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.9x - 15.6x | 15.2x |
| Forward P/E multiples | 22.0x - 53.9x | 38.0x |
| Fair Price | (56.40) - (39.77) | (68.35) |
| Upside | -423.6% - -328.2% | -492.2% |
| Date | EV/EBITDA |
| 2026-01-02 | -6.65 |
| 2025-12-31 | -7.00 |
| 2025-12-30 | -7.02 |
| 2025-12-29 | -7.15 |
| 2025-12-26 | -7.13 |
| 2025-12-24 | -7.15 |
| 2025-12-23 | -7.12 |
| 2025-12-22 | -7.14 |
| 2025-12-19 | -6.83 |
| 2025-12-18 | -6.63 |
| 2025-12-17 | -6.71 |
| 2025-12-16 | -6.95 |
| 2025-12-15 | -7.02 |
| 2025-12-12 | -7.04 |
| 2025-12-11 | -7.04 |
| 2025-12-10 | -7.25 |
| 2025-12-09 | -7.22 |
| 2025-12-08 | -7.96 |
| 2025-12-05 | -6.66 |
| 2025-12-04 | -6.64 |
| 2025-12-03 | -6.18 |
| 2025-12-02 | -5.99 |
| 2025-12-01 | -6.21 |
| 2025-11-28 | -6.51 |
| 2025-11-26 | -6.32 |
| 2025-11-25 | -6.24 |
| 2025-11-24 | -6.30 |
| 2025-11-21 | -6.15 |
| 2025-11-20 | -5.60 |
| 2025-11-19 | -5.22 |
| 2025-11-18 | -4.58 |
| 2025-11-17 | -4.62 |
| 2025-11-14 | -4.63 |
| 2025-11-13 | -4.49 |
| 2025-11-12 | -4.39 |
| 2025-11-11 | -4.65 |
| 2025-11-10 | -4.42 |
| 2025-11-07 | -4.44 |
| 2025-11-06 | -4.52 |
| 2025-11-05 | -4.49 |
| 2025-11-04 | -4.42 |
| 2025-11-03 | -4.56 |
| 2025-10-31 | -4.68 |
| 2025-10-30 | -4.62 |
| 2025-10-29 | -4.20 |
| 2025-10-28 | -4.28 |
| 2025-10-27 | -4.31 |
| 2025-10-24 | -3.97 |
| 2025-10-23 | -3.70 |
| 2025-10-22 | -3.79 |